Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
Medicinova, Inc. (NASDAQ: MNOV), headquartered in La Jolla, California, is a clinical-stage biopharmaceutical company focused on acquiring and developing promising small-molecule therapeutics to treat diseases with unmet medical needs. Specializing in therapies for neurological disorders and fibrotic diseases, Medicinova has a strategic emphasis on the U.S. market.
Medicinova’s robust product portfolio includes several innovative drugs in late-stage clinical development. These include MN-001 (tipelukast) and MN-166 (ibudilast), both of which boast multiple mechanisms of action and strong safety profiles. MN-166 (ibudilast) is in Phase 3 clinical trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is Phase 3-ready for progressive multiple sclerosis (MS). It is also being evaluated in Phase 2 trials for Long COVID, substance dependence, and other neurodegenerative diseases.
The company recently received a series of new patents, significantly extending its intellectual property protection. One such patent covers the use of MN-166 for treating macular injury and decreasing macular volume loss associated with progressive multiple sclerosis. Another patent covers the formulation of MN-166 in extended-release oral forms, which is expected to improve patient compliance and reduce side effects.
Medicinova has demonstrated the potential of MN-166 in ophthalmic neurodegenerative diseases, supported by positive data from various animal model studies and the SPRINT-MS Phase 2b trial. Additionally, MN-166 is under investigation for its efficacy in treating glioblastoma, Long COVID, chemotherapy-induced peripheral neuropathy (CIPN), and substance use disorder.
Alongside its development efforts, Medicinova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. This financial support underscores the promise and potential of its therapies to address critical medical needs.
For more information or investor inquiries, please contact Geoff O'Brien, Vice President at info@medicinova.com.
MediciNova, Inc. has announced a modification to its contract with BARDA to repurpose MN-166 (ibudilast) as a potential medical countermeasure against chlorine gas-induced lung damage. The contract extension lasts until May 31, 2023. MN-166, a small molecule compound, is in late-stage clinical development for various neurodegenerative diseases and is being evaluated for ARDS. MediciNova is focused on developing novel therapies for inflammatory and neurodegenerative diseases, with MN-166 currently in Phase 3 trials for ALS and DCM.
MediciNova, Inc. announced research findings from the glioblastoma clinical trial MN-166-GBM-1201, presented by Dr. Justin Lathia at the 20th Annual World Congress of SBMT. The study analyzed tumor tissues to identify predictors of treatment response to MN-166 and temozolomide. Results showed that responders had lower CD3+ T cell percentages and trends in CD74 expression compared to non-responders. Dr. Lathia highlighted MN-166's potential in enhancing CD3+ infiltration in glioblastoma patients. Chief Medical Officer Kazuko Matsuda noted the significance of these findings in addressing the challenges of glioblastoma treatment.
MediciNova has received authorization from Health Canada to initiate a multi-center, randomized clinical trial for MN-166 (ibudilast) targeting Long COVID treatment, under the RECLAIM trial. This Phase 2/3 trial aims to evaluate various therapies, including MN-166, with about 800-1000 patients expected to participate across Canada. The study will monitor improvements in patients' physical health over a 6-month period. This development highlights a significant unmet medical need for effective Long COVID interventions, potentially enhancing MediciNova's pipeline focused on inflammatory and neurodegenerative diseases.
MediciNova, Inc. has completed enrollment in a Phase 2b clinical trial of MN-166 (ibudilast) aimed at treating alcohol use disorder (AUD). This trial, funded by the National Institute on Alcohol Abuse and Alcoholism, includes 102 participants who will take MN-166 or a placebo over 12 weeks. The primary goal is to evaluate the reduction in heavy drinking days. Results from recent studies suggest MN-166 is a safe, promising treatment for AUD. The company is anticipating topline results following participant follow-up.
MediciNova announced the completion of enrollment in its Phase 2 clinical trial of MN-166 (ibudilast) for glioblastoma at Dana-Farber Cancer Institute. This trial includes a dose-escalation phase to determine safety and a fixed-dose phase to evaluate efficacy combined with temozolomide (TMZ). Preliminary results will be revealed at the 20th Annual World Congress of SBMT from February 16-19, 2023. Chief Medical Officer, Kazuko Matsuda, expressed optimism about potential predictors of treatment response and indicated further findings will be shared post-conference.
FAQ
What is the current stock price of Medicinova (MNOV)?
What is the market cap of Medicinova (MNOV)?
What is Medicinova, Inc.?
What are the key areas of focus for Medicinova?
What are the main products in Medicinova's pipeline?
What is MN-166 (ibudilast)?
What recent achievements has Medicinova made?
What financial backing does Medicinova have?
How does MN-166 (ibudilast) work?
What is the significance of Medicinova's new patents?
Where is Medicinova headquartered?
How can investors contact Medicinova?
